Tff Pharmaceuticals Inc (TFFP) Return on Equity ROE from the third quarter 2024 to third quarter 2023 and annually, average high and low, overall ranking from Sep 30 2024 to Sep 30 2023 - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Tff Pharmaceuticals Inc  (NASDAQ: TFFP)

Tff Pharmaceuticals Inc's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Tff Pharmaceuticals Inc in the third quarter 2024?
Tff Pharmaceuticals Inc recorded a cumulative net loss of $-19 million during 12 months ending in the third quarter 2024, resulting in a negative return on equity (ROE) of -310.17%.

Within the Major Pharmaceutical Preparations industry 332 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2024 from 3531 to 3687.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Sep 30 2024)
III. Quarter		 (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter
Y / Y Equity Change -77.09 % -52.15 % -67.94 % -58.19 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions -19 -19 -20 -21 40
Return On Equity (TTM) -310.17 % -225.16 % -195.15 % -163.15 % 242.93 %
TFFP's Total Ranking # 3687 # 3531 # 0 # 3110 #
Equity (TTM) in Millions 3 6 5 10 14
Seq. Equity Change -46.62 % 10.8 % -44.55 % -30.12 % 11.47 %
Seq. Net Income Change - - - - -

Back to TFFP Management Effectiveness >> TFFP's 5 Years Annual ROE >> Compare TFFP ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 333
Sector # 725
Overall # 3687

Return On Equity Statistics
High Average Low
-19.29 %
-123.75 %
-259.46 %
(Mar 31 2022)   (Sep 30 2024)



  News about Tff Pharmaceuticals Inc Return on Equity ROE

TFF Pharmaceuticals A Promising Influenza Vaccine Facing Financial Headwinds,

In a significant development for public health, TFF Pharmaceuticals recently announced promising preclinical data from its bivalent universal influenza vaccine candidates. Manufactured by TFF, these vaccine candidates demonstrated the ability to induce neutralizing antibody titers in ferrets against the H1 and H3 influenza strains following intranasal immunization. However, beneath the promising vaccine data lies a troubling financial landscape for the company, highlighted by a cumulative net loss of $20 million in the twelve months leading up to the second quarter of 2024 and a staggering negative return on equity (ROE) of -211.48%. Positive Preclinical Data TFF Pharmaceuticals’ latest announcement regarding its bivalent universal influenza vaccine candidates represents a potential breakthrough in influenza prevention strategies. Traditional vaccines often target specific strains, making it imperative to reformulate annually based on circulating virus strains. In contrast, the TFF approach aims to stimulate broad immune responses through its universal vaccine candidates. The preclinical data from ferret studies indicate that the intranasal immunization effectively generates neutralizing antibodies, suggesting that these vaccine candidates may offer robust protection against both H1 and H3 strains that commonly circulate during flu seasons.



TFFP Annual Return On Equity (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019
Total Equity in Millions 10 23 39 37 28
Y / Y Equity Change -58.19 % -40.94 % 3.74 % 35.07 % -
Net Income in Millions -21 -32 -31 -19 -12
Y / Y Net Income Change - - - - -
Return On Equity -222.05 % -138.86 % -80.13 % -49.72 % -42.94 %

Back to TFFP Management Effectiveness >> TFFP's 5 Years Annual ROE >> Compare TFFP ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
TFFP's' Return on Equity at Yahoo Finance
TFFP's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for TFFP's Competitors
Subscribers only: Roe for Tff Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Equity for TFFP's Customers




Companies with similar Return On Equity at Sep 30 2024, within Healthcare Sector ROE

Date modified: 2026-09-26T07:40:00+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.